|
|
 |
|
Viewing report
|
|
|
|
Active Transdermal Delivery Systems: Evolving Technology, Expanding Opportunities
Greystone Associates, Feb 2011
The advantages of transdermal drug delivery for improving patient compliance, particularly for the treatment of chronic conditions, are well known. But growth of transdermal delivery has been restricted by the need to limit candidate drugs to molecules small enough to effectively pass through the stratum corneum, a limitation that excludes passive transdermal patches as a viable option for the growing number of protein and peptide therapeutic compounds that will represent an increasing share of future NCEs. To expand the limits of transdermal drug delivery, developers are employing energy sources such as ultrasound, heat and electrical current to affect active transport through the skin. Another approach is the modification or removal of surface skin layers, a group of technologies collectively referred to as microporation, which can be used alone or in conjunction with energy-enabled devices to expand the size and type of drug molecules capable of transdermal delivery. These techniques can increase the upper molecular size limit dramatically, opening up a host of opportunities for transdermal delivery.
Highlights
- Analyzes and evaluates active transdermal device technology and commercial active transdermal products and assesses the market potential for existing and probable future products
- Examines active transdermal system design issues and evolving market factors
- Forecasts the impact of active transdermal systems on drug delivery markets
- Provides forecasts of active transdermal delivery by market segment to 2014
- Profiles active transdermal system market participants, their technology, product development activity, and business strategies
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
